Skip to main content
Clinical Trials/NCT03002324
NCT03002324CompletedNot Applicable

Tailoring of Vaccine-Focused Messages: Moral Foundations and Disease Salience - Part 2

Emory University1 site in 1 country1,320 target enrollmentStarted: January 1, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
1,320
Locations
1
Primary Endpoint
Intent to have their child vaccinated against HPV

Study Overview

Brief Summary

This study is the second phase of a trial examining decision making about vaccines. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current Centers for Disease Control and Prevention (CDC) human papillomavirus (HPV) message, a new cervical cancer focused message developed by the study team, and a non-vaccine related control passage among parents of adolescent females. The goal of the trial will be to determine if the new cervical cancer framed message has an increased impact on intent to have daughters receive the HPV vaccine over the trial period as compared to the current CDC message used in the field. Additionally, the researchers will examine the impact both the CDC message and the new message individually have on intent to vaccinate when compared to the non-vaccine related control message.

The participant's vaccine beliefs and intent to vaccinate will be assessed through an online survey at baseline. Two weeks later, participants will be randomized to view one of the three messages: the current CDC message, the cervical cancer framed message, or a non-vaccine related control message. Immediately afterwards, vaccine beliefs and intent to vaccinate will be assessed to determine the impact of the message.

Detailed Description

Genital human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Most HPV infections are asymptomatic and clear on their own within 2 years but persistent infections can lead to diseases, including several cancers. Cervical cancer is the most common cancer caused by HPV infection, and virtually all cervical cancers can be attributed to HPV infection. There is no cure for HPV, but HPV can be prevented through vaccination. Current recommendations from the Advisory Committee on Immunization Practices (ACIP) state that the HPV vaccine may be given starting at 11-12 years of age for boys and girls, through age 26. Despite the safety and efficacy of this vaccine, the coverage among adolescents aged 11-17 years old remains low. Attaining high vaccination rates among adolescents is essential to decreasing the burden of disease due to cervical cancer, and other cancers caused by HPV.

Parental decision to vaccinate their children, specifically with the HPV vaccine, can be tied to multiple constructs of the Health Belief Model. These include perceived susceptibility of HPV infection (is my child at risk of infection), perceived benefit, and perceived severity (of disease, and of vaccine related adverse events). This would suggest that messaging surrounding the HPV vaccination should be highly salient within these constructs. The current message tied to the HPV vaccine presented by the Centers for Disease Control (CDC) has a focus on HPV as an infection and is clinical in nature. In a randomized trial, parents given information about HPV were no more likely to be accepting of an HPV vaccine and no more likely to get their child vaccinated. Based on this literature, the researchers hypothesize that reframing the message to promote HPV vaccination as a means of protection against cervical cancer will impact intent to vaccinate among parents of adolescent females (aged 11-17 years old).

In the first phase of this study the researchers assessed how appealing to different moral foundations impacted attitudes towards vaccination and intent to vaccinate. For this phase of this study, the researchers will conduct a 3-arm randomized trial to compare the current CDC HPV, a cervical cancer focused message developed by the study team, and a non-vaccine related control passage among parents of adolescent females. The goal of the trial will be to determine if the new cervical cancer framed message has an increased impact on intent to have daughters receive the HPV vaccine over the trial period as compared to the current CDC message. Additionally, the researchers will examine the impact both the CDC message and the new message have on intent to vaccinate when compared to the non-vaccine related control message.

The participant's vaccine beliefs and intent to vaccinate will be assessed through an online survey at baseline. Two weeks later, participants will be randomized to view one of the three messages: the current CDC message, the cervical cancer framed message, or a non-vaccine related control message. Immediately afterwards, vaccine beliefs and intent to vaccinate will be assessed to determine the impact of the message.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Have at least one daughter between 9 and 17 years of age (inclusive)
  • •Reside in the United States

Exclusion Criteria

  • •Have previously participated in the disease salience phase of this study

Arms & Interventions

Current CDC Message Arm

Active Comparator

Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.

Intervention: Baseline Survey (Behavioral)

Current CDC Message Arm

Active Comparator

Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.

Intervention: Current CDC Message (Behavioral)

Current CDC Message Arm

Active Comparator

Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.

Intervention: Post-Intervention Survey (Behavioral)

Cervical Cancer Message Arm

Experimental

Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.

Intervention: Baseline Survey (Behavioral)

Cervical Cancer Message Arm

Experimental

Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.

Intervention: Cervical Cancer Message (Behavioral)

Cervical Cancer Message Arm

Experimental

Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.

Intervention: Post-Intervention Survey (Behavioral)

Control Message

Sham Comparator

Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.

Intervention: Baseline Survey (Behavioral)

Control Message

Sham Comparator

Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.

Intervention: Control Message (Behavioral)

Control Message

Sham Comparator

Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.

Intervention: Post-Intervention Survey (Behavioral)

Outcomes

Primary Outcomes

Intent to have their child vaccinated against HPV

Time Frame: Week 2

Number of caregivers intending to have their daughter(s) receive the HPV vaccine

Overall change in attitude towards the human papilloma virus (HPV) vaccine

Time Frame: Week 2

Number of caregivers experiencing a change in attitude towards the HPV vaccine

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Saad B. Omer, MBBS, MPH, PhD

Professor

Emory University

Study Sites (1)

Loading locations...

Similar Trials